Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: A location method and system are provided for obtaining a location of a terminal. The location method comprises, when a gateway mobile location center is unable to obtain an address of a mobile switching center (MSC) to which the terminal belongs from a home location register (HLR) in a core network by sending location selecting routing signaling, after sending short message type information to trigger the home location register to update the location of the terminal and obtaining the address of the MSC to which the terminal belongs, the gateway mobile location center obtaining location parameters of the terminal by sending location request signaling, and calculating location information of the terminal.

Abstract: A location method and system are provided for obtaining a location of a terminal. The location method comprises, when a gateway mobile location center is unable to obtain an address of a mobile switching center (MSC) to which the terminal belongs from a home location register (HLR) in a core network by sending location selecting routing signaling, after sending short message type information to trigger the home location register to update the location of the terminal and obtaining the address of the MSC to which the terminal belongs, the gateway mobile location center obtaining location parameters of the terminal by sending location request signaling, and calculating location information of the terminal.